SIRT6 and bladder transitional cell carcinoma: Pharmacological inhibition of UHRF1 markedly attenuates the malignant progression of SIRT6-deficient BLCA, suggesting that targeting the SIRT6-UHRF-glycolysis axis represents a novel therapeutic vulnerability.